Literature DB >> 7451981

Tumor-associated antigens in spent medium of human melanoma cells: immunochemical characterization with xenoantisera.

D R Galloway, R P McCabe, M A Pellegrino, S Ferrone, R A Reisfeld.   

Abstract

Xenoantisera to human melanoma cells and to partially purified melanoma-associated antigens were coupled to protein A-bearing Staphylococcus Aureus or protein A-Sepharose and used as immunoadsorbents for the indirect immunoprecipitation of intrinsically radiolabeled proteins released into culture medium from various cultured human tumor and nontumor cell lines. These radiolabeled immunoprecipitates when analyzed by SDS-PAGE revealed highly reproducible molecular profiles of proteins and glycoproteins released by various cultured tumor lines and control cells into their spent culture media. A comparison of molecular profiles together with data indicating the binding specificity of known xenoantisera produced against human melanoma cells or their extracts led to the discovery of 2 macromolecules that are associated with human melanoma cells; a glycoprotein with a subunit m.w. of 240,000 (240K) and a single-chain glycoprotein of 94,000 (94K) m.w. also found in association with human carcinoma cells are described in this report.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7451981

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

1.  Serial studies of autologous antibody reactivity to melanoma. Relationship to clinical course and circulating immune complexes.

Authors:  D R Vlock; J M Kirkwood
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

2.  Monoclonal antibodies to different epitopes on a prostate tumor-associated antigen. Implications for immunotherapy.

Authors:  K S Webb; J L Ware; S F Parks; W H Briner; D F Paulson
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

Review 3.  Human tumor-associated antigens identified by monoclonal antibodies.

Authors:  K E Hellström; I Hellström; J P Brown
Journal:  Springer Semin Immunopathol       Date:  1982

4.  Production of a tumor-specific xenoantiserum from partially purified immunoprotective tumor antigen.

Authors:  T Tanaka; H Yamagishi; N R Pellis; B D Kahan
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

5.  Heterogeneity of human melanoma-associated antigens defined by monoclonal antibodies and conventional xenoantisera.

Authors:  B S Wilson; N E Kay; K Imai; S Ferrone
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

6.  National Pancreatic Cancer Project. Workshop on pancreatic tumor markers.

Authors:  H Z Kupchik; R A Reisfeld; V L Go
Journal:  Dig Dis Sci       Date:  1982-01       Impact factor: 3.199

7.  Immune response of chimpanzee to purified melanoma 250 kilodalton tumor-associated antigen.

Authors:  G M Stuhlmiller; T L Darrow; D M Haupt; H F Seigler
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

8.  Unique glycoprotein-proteoglycan complex defined by monoclonal antibody on human melanoma cells.

Authors:  T F Bumol; R A Reisfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1982-02       Impact factor: 11.205

9.  Prognostic role of antibody reactivity to melanoma.

Authors:  D R Vlock; R DerSimonian; J M Kirkwood
Journal:  J Clin Invest       Date:  1986-04       Impact factor: 14.808

10.  Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan.

Authors:  G Pluschke; M Vanek; A Evans; T Dittmar; P Schmid; P Itin; E J Filardo; R A Reisfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.